Moore Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Moore Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250,000	Closed	-$643K	–	584
2024 Q2	$643K	Hold	250,000	–	–	0.01%	329
2024 Q1	$1.23M	Buy	250,000 +100,000	+67%	+$592K	0.02%	294
2023 Q4	$1.32M	Sell	150,000 -10,000	-6%	-$81.9K	0.02%	255
2023 Q3	$1.84M	Buy	160,000 +105,000	+191%	+$2.02M	0.03%	256
2023 Q2	$1.39M	Buy	+55,000	New	+$1.71M	0.02%	283
2014 Q3	–	Sell	-100,000	Closed	-$3.4M	–	542
2014 Q2	$3.4M	Buy	+100,000	New	+$3.13M	0.08%	230

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Moore Capital Management's RVNC Position: Q3 2024 in Review

Moore Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 250,000 shares — an estimated $643K sold.

Moore Capital Management first reported a position in RVNC in Q2 2014 and held it in 6 quarters. The position peaked at $3.4M in Q2 2014. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Moore Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 250,000 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $643K.
Moore Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 6 quarters.
Moore Capital Management's Revance Therapeutics, Inc. position peaked at $3.4M in Q2 2014.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.